Characterization of Breg Cells

NCT02615951 | Completed

• 1 other identifier: 9461
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Recently, it has been shown that B cells could also have regulatory functions through the secretion of interleukin 10 (IL-10). They are called the B regulatory cells (Breg). In the mouse model the most commonly used of rheumatoid arthritis, collagen-induced arthritis (CIA), the transfer Breg helps prevent the development of CIA and cure established arthritis. The investigators have recently shown that Breg were decreased in patients with RA compared to controls and that the rate of Breg was inversely correlated with disease activity and autoantibody. These results thus suggest that the lack of IL-10 secretion by B cells plays an important role in the pathophysiology of RA. Nevertheless, in humans, the Breg remain poorly understood. The main objective of this project is to better characterize the B capable of producing IL-10 both in subjects with RA and controls. Understanding which induces the secretion of IL-10 by B could allow to consider new therapeutic approaches in autoimmune diseases, including in RA. The investigators therefore aim to identify nutrient transporters, chemokine receptors, genes and surface proteins differentially expressed between Breg and other B cells in patients with RA and in controls.

Conditions

Healthy Volunteers; Arthritis, Rheumatoid

Keywords

Regulatory B cells (Breg); Genes; Cell surface proteins; Nutrient transporters; Chemokine receptors

Outcome Measures

Primary Outcomes (1)

• Identification of nutrient transporters' and of chemokine receptors' differentially expressed between Breg and other B cells in patients with RA

  Comparison between Breg (B IL-10+) and IL-10 non secreting B lymphocytes (B IL-10 -) in RA patient of : * Medium fluorescence intensity of B lymphocytes for ASCT2, Glut1, PiT1, PiT2, RFT1\&3 * Percentage of B lymphocytes expressing chemokine receptors CCR4, CCR7, CCR9, CXCR3, CXCR4 and CXCR5

  after analysis of the blood sample from the subject selected for the primary outcome mesure. Estimated at half a year after subject recruitement started

Secondary Outcomes (4)

• Identification of genes and surface receptors expressed differentially between Breg and others B cells in patients with RA

  Estimated at 6 month after end of subject recruitement

• Identification of nutrient transporters and chemokine receptors expressed differentially between Breg and others B cells in control patients

  Estimated at 6 month after end of subject recruitement

• : Identification of genes and surface receptors expressed differentially between Breg and others B cells in control patients

  Estimated at 6 month after end of subject recruitement

• Comparison of nutrient transporters, chemokine receptors, gene and protein surface expression expressed between Breg in patients with RA and Breg in control patients

  Estimated at 6 month after end of subject recruitement

Study Arms (5)

Nutrient transporters study

OTHER

Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of nutrient transporters expression

Other: blood sampling

Chemokine receptors study

OTHER

Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of chemokine receptors expression

Other: blood sampling

Genes study

OTHER

Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of genes expression

Other: blood sampling

Protein surface study

OTHER

Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of protein surface expression

Other: blood sampling

Protein surface & genes data validation

OTHER

Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure for validation of the data from "protein surface study" and "genes study" arms analysis.

Other: blood sampling

Interventions

blood sampling OTHER

Blood sample retrieval for biological and genetic analysis and comparison

Chemokine receptors study; Genes study; Nutrient transporters study; Protein surface & genes data validation; Protein surface study

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• RA responding to ACR/EULAR 2010 criteria

You may not qualify if:

• steroid\> 10 mg/d
• previous use of biological disease-modifying antirheumatic drug (DMARD)
• age\<18 years

Sponsors & Collaborators

• University Hospital, Montpellier: lead
• Centre Hospitalier Universitaire de Nīmes: collaborator
• Institut de Génétique Moléculaire de Montpellier: collaborator

Study Sites (1)

Regional University Hospital

Montpellier, Hérault, 34295, France

Location

MeSH Terms

Conditions

Arthritis, Rheumatoid

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Officials

• Claire I Daien, MD PhD

  Montpellier teaching hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 28, 2015
• First Posted: November 26, 2015
• Study Start: October 2, 2015
• Primary Completion: September 10, 2018
• Study Completion: September 10, 2018
• Last Updated: December 29, 2021

Record last verified: 2021-12

Locations

FR (1)